George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)
August 1, 2022 10:15 AM EDTUpdated 10:40 AM
R&D
Pharma
Coronavirus

Re­gen­eron ends four clin­i­cal tri­als of its rolled-back Covid-19 an­ti­body

Kyle LaHucik

Senior Reporter

Re­gen­eron has ter­mi­nat­ed four stud­ies of its mon­o­clon­al an­ti­body com­bi­na­tion, known as RE­GEN-COV, in re­cent days, months af­ter the FDA

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times